Some critics of the 340B drug discount program say it should be phased out because millions of people will get health coverage under health care reform. This argument ignores that other parts of the Affordable Care Act (ACA) are squeezing public and private nonprofit hospitals' finances—making hospitals' continued access to 340B drug discounts more important than … [Read more...]
AIDS Group Files Second Suit Alleging 340B Overcharges
Says Johnson & Johnson wrongly denied it up to $2 million in discountsNovember 1, 2013—The AIDS Healthcare Foundation (AHF) has filed suit in California against drug manufacturer Johnson & Johnson (J&J) and its Janssen Therapeutics and Janssen Biotech units to recover as much as $2 million in 340B drug discounts that it claims the family of companies failed to provide it between 2005 and 2012. … [Read more...]
Medicare Outpatient Payment Final Rule Delayed Due to Sequester
In July, CMS proposed continuing ASP plus 6% rate for specified high-cost drugsOctober 31, 2013—Final regulations setting next year's Medicare reimbursement rates for hospital outpatient services and specified high-cost drugs will be held up for about a month due to the recent partial government shutdown. … [Read more...]
Judge Agrees to Speed Up 340B Orphan Drug Lawsuit
All filings in advance of hearing are due by Jan. 17October 31, 2013—A federal district judge has approved the federal government's and drug manufacturers' joint motion to speed up the industry’s lawsuit challenging the legality of the 340B orphan drug exclusion regulation. … [Read more...]
PhRMA and HHS Want to Resolve 340B Orphan Drug Suit Quickly
If judge agrees, ruling on the merits of industry's arguments could come as soon as JanuaryOctober 24, 2013—The federal government and drug manufacturers have agreed to fast-track the industry's lawsuit challenging the legality of the 340B orphan drug exclusion regulation. … [Read more...]
Investor’s Business Daily Publishes Our Defense of 340B
Investor's Business Daily (IBD) recently published a diatribe against 340B hospitals and the 340B program by Sally C. Pipes, who heads the "think tank" Pacific Research Institute. Among other fulminations, Pipes said 340B is an "ungainly operation fattening the bottom lines of pharmacies and hospitals," "fails to actually help vulnerable patients," and "represents an … [Read more...]
RAND Corp. Launches 340B Research Project
Leaders say they aim to provide objective, nonpartisan analysisOctober 22, 2013—The RAND Corp. announced yesterday that it is launching a project to study and make recommendations for improving the 340B program. Organizers said one of their first tasks will be to submit comments on forthcoming 340B regulations due to be published in the coming months. … [Read more...]